EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Effectiveness of switching from dipeptidyl peptidase‐4 inhibitor to oral glucagon‐like peptide‐1 receptor agonist in Japanese participants with type 2 diabetes mellitus: Prospective observational study using propensity score matching

Hideyuki Iwamoto, Tomohiko Kimura iD, Yoshiro Fushimi, Masahiro Iwamoto, Fuminori Tatsumi, Junpei Sanada, Yuichiro Iwamoto iD, Yukino Katakura, Masashi Shimoda iD, Shuhei Nakanishi, Tomoatsu Mune, Kohei Kaku iD und 1 weitere

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15784 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Hideyuki Iwamoto und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors, Propensity Score, Glucagon-Like Peptides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Recently, the development of the oral glucagon‐like peptide‐1 receptor agonist semaglutide has drawn a great deal of attention. This study aimed to compare the effectiveness of oral glucagon‐like peptide‐1 receptor agonist semaglutide and dipeptidyl peptidase‐4 (DPP‐4) inhibitors on glycaemic control and several metabolic parameters in patients with type 2 diabetes mellitus over a 6‐month period.

Methods

Fifty‐nine participants were included, and we compared various clinical parameters between before and after switching from DPP‐4 inhibitors to oral semaglutide in ‘study 1’ (pre‐post comparison) and set the control group using the propensity score matching method in ‘study 2’.

Results

In ‘study 1’, 6 months after the switching, the glycated haemoglobin value was significantly reduced from 7.5% to 7.0%, and the body mass index was also decreased from 29.7 kg/m 2 to 28.8 kg/m 2 . Such effects were more clearly observed in participants whose glycaemic control was poor. In ‘study 2’, after 1:1 propensity score matching, 51 participants from each group were matched, and glycaemic control as well as body weight management were improved in the switching group compared with the DPP‐4 inhibitor continuation group over the 6‐month observation period.

Conclusion

In this study, including obese participants with poor glycaemic control, switching DPP‐4 inhibitors to oral semaglutide showed more beneficial effects on both glycaemic and weight control, irrespective of age, body weight and diabetes duration. Therefore, we should bear in mind that it would be better to start using an oral semaglutide in clinical practice, particularly in obese participants with poor glycaemic control with DPP‐4 inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsPropensity ScoreGlucagon-Like PeptidesGlycated HemoglobinHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsHumansMaleFemaleMiddle AgedProspective StudiesAgedJapanDrug SubstitutionTreatment OutcomeBlood GlucoseGlycemic ControlAdministration, OralEast Asian PeopleSemaglutide

Stichwörter der Autor:innen

body mass indexdipeptidyl peptidase‐4 inhibitorsglucagon‐like peptide‐1 receptor agonistglycated haemoglobinoral semaglutide

Substanzen

Dipeptidyl-Peptidase IV InhibitorsGlucagon-Like PeptidesGlycated HemoglobinHypoglycemic AgentsBlood GlucoseGlucagon-Like Peptide-1 Receptor AgonistsSemaglutidehemoglobin A1c protein, human

Autor:innen und Institutionen

  • Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, Japan.
  • Iwamoto Medical Clinic, Kagawa, Japan.

ORCID-Profile: Tomohiko Kimura, Yuichiro Iwamoto, Masashi Shimoda, Kohei Kaku

Zitieren

APA

Iwamoto, H., Kimura, T., Fushimi, Y., Iwamoto, M., Tatsumi, F., Sanada, J., Iwamoto, Y., Katakura, Y., Shimoda, M., Nakanishi, S., Mune, T., Kaku, K., & Kaneto, H. (2024). Effectiveness of switching from dipeptidyl peptidase‐4 inhibitor to oral glucagon‐like peptide‐1 receptor agonist in Japanese participants with type 2 diabetes mellitus: Prospective observational study using propensity score matching. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15784

Vancouver

Iwamoto H, Kimura T, Fushimi Y, Iwamoto M, Tatsumi F, Sanada J, et al. Effectiveness of switching from dipeptidyl peptidase‐4 inhibitor to oral glucagon‐like peptide‐1 receptor agonist in Japanese participants with type 2 diabetes mellitus: Prospective observational study using propensity score matching. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15784

BibTeX
@article{Iwamoto2024,
  author = {Iwamoto, Hideyuki and Kimura, Tomohiko and Fushimi, Yoshiro and Iwamoto, Masahiro and Tatsumi, Fuminori and Sanada, Junpei and Iwamoto, Yuichiro and Katakura, Yukino and Shimoda, Masashi and Nakanishi, Shuhei and Mune, Tomoatsu and Kaku, Kohei and Kaneto, Hideaki},
  title = {Effectiveness of switching from dipeptidyl peptidase‐4 inhibitor to oral glucagon‐like peptide‐1 receptor agonist in Japanese participants with type 2 diabetes mellitus: Prospective observational study using propensity score matching},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15784}
}
Kostenlos starten →